Last Updated: August 9, 2026

CLINICAL TRIALS PROFILE FOR GLYXAMBI

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for GLYXAMBI

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06932159 ↗	Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets	COMPLETED	Humanis Saglk Anonim Sirketi	PHASE1	2024-12-23	An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
NCT07039890 ↗	To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.	COMPLETED	Humanis Saglk Anonim Sirketi	PHASE1	2025-03-08	To compare and evaluate the oral bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg film-coated tablets with that of Glyxambi 10 mg/ 5 mg film-coated tablets in healthy, adult, human subjects under fasting conditions.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for GLYXAMBI

Condition Name

Chart
Table

Condition Name for GLYXAMBI
Intervention	Trials
Type 2 Diabetes Mellitus (T2DM)	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for GLYXAMBI
Intervention	Trials
Diabetes Mellitus, Type 2	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for GLYXAMBI

Trials by Country

Map
Table

Trials by Country for GLYXAMBI
Location	Trials
India	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for GLYXAMBI

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for GLYXAMBI
Clinical Trial Phase	Trials
PHASE1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for GLYXAMBI
Clinical Trial Phase	Trials
COMPLETED	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GLYXAMBI

Sponsor Name

Chart
Table

Sponsor Name for GLYXAMBI
Sponsor	Trials
Humanis Saglk Anonim Sirketi	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for GLYXAMBI
Sponsor	Trials
INDUSTRY	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.